MedDataX Logo

Effect of JNJ 31001074 on Urge to Drink in Alcohol-Dependent Adults

NCT ID: NCT01362699

Last Updated: 2012-04-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2011-08-31

Study Completion Date

2012-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess whether JNJ-31001074 taken for 7 days reduces the urge to drink alcohol in alcohol-dependent study participants who are not seeking treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will evaluate whether JNJ 31001074 reduces the urge to drink alcohol in non treatment seeking, adult study participants with current alcohol dependence. Individuals who meet criteria for study participation will be randomly assigned to one of two treatment groups (tablets containing JNJ 31001074 or placebo tablets with no active ingredients) in a 1:1 ratio. Treatment group assignment will not be known by study participants or study staff. Baseline assessments will be recorded and participants will return to the clinic for testing on the last day of taking their assigned study medication for 7 days at home. Alcohol use is not allowed for 3 days prior to this end-of-dosing testing. During this test, their urge to drink alcohol and their mood will be measured while they view various computer images and then are presented with (but do not drink) either a favorite alcoholic beverage or water. Other measures will be collected during the study to evaluate the safety and tolerability of the study medication, including potential effects on sleep, as well as measures of thinking and cigarette smoking. Participants will return for a follow-up visit approximately 1 week after finishing the study medication and completing the clinic assessment above. Study participants will take one 3-mg tablet of JNJ-31001074 or matching placebo in the morning, preferably with food, for 7 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcoholism

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Alcoholism Alcohol-Related Disorders Substance-Related Disorders Mental Disorders Alcohol Dependence JNJ-31001074 Bavisant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

JNJ-31001074

Group Type EXPERIMENTAL

JNJ-31001074

Intervention Type DRUG

Type=exact number, unit=mg, number=3, form=tablet, route=oral use. One tablet once daily for 7 days.

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Form=tablet, route=oral administration. One tablet once daily for 7 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

JNJ-31001074

Type=exact number, unit=mg, number=3, form=tablet, route=oral use. One tablet once daily for 7 days.

Intervention Type DRUG

Placebo

Form=tablet, route=oral administration. One tablet once daily for 7 days.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female
* Currently alcohol dependent but not seeking treatment
* Meets study criteria for amount of alcohol consumed
* Otherwise healthy
* Urge to drink increased by the presence of alcohol
* Able to complete and understand questionnaires and study procedures in English
* Willing and able to comply with the study requirements, including a 3-day period of alcohol abstinence and use of highly effective contraceptive methods
* Signed informed consent.

Exclusion Criteria

* Pregnant or breast-feeding
* Significant medical or psychiatric conditions other than alcohol dependence
* History of, or at risk of, medically significant alcohol withdrawal syndrome
* Dependent on substances other than alcohol , nicotine or caffeine
* Smokes more than 1 pack of cigarettes per day or consumes more than 500 mg caffeine per day
* Has glaucoma, cataracts, a history of eye inflammation, eye injury, or eye surgery other than to correct vision
* Treatment in the past 1 month prior to screening with disulfiram (Antabuse), acamprosate (Campral), naltrexone (ReVia or Vivitrol), or topiramate (Topamax)
* In need of or currently taking any psychoactive medications
Minimum Eligible Age

21 Years

Maximum Eligible Age

62 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Scripps Research Institute

OTHER

Sponsor Role collaborator

Janssen Research & Development, LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Janssen Research & Development, LLC

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Janssen Research & Development, LLC C. Clinical Trial

Role: STUDY_DIRECTOR

Janssen Research & Development, LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

La Jolla, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

31001074ALC2001

Identifier Type: OTHER

Identifier Source: secondary_id

CR018802

Identifier Type: -

Identifier Source: org_study_id